Literature DB >> 6732337

Rebound vasospasm after coronary revascularization in association with calcium antagonist withdrawal.

R M Engelman, I Hadji-Rousou, R H Breyer, P Whittredge, W Harbison, R V Chircop.   

Abstract

Four patients experienced life-threatening coronary vasospasm following discontinuation of calcium channel blocking medication at the time of coronary revascularization. The last dose of the calcium blocker in each instance was administered between 8 and 18 hours before operation. Two of the patients were receiving diltiazem (60 mg four times a day) and 2, nifedipine (20 mg four times a day). During this same period, 16 patients had received diltiazem (12.5% incidence of vasospasm) and more than 100 patients, nifedipine (less than 2% incidence). In 3 of the 4 patients, coronary spasm was identified by electrocardiogram and documented as the cause of ischemia in the distribution of a nondiseased right coronary artery. In the fourth patient, spasm had occurred in the distribution of a bypassed left anterior descending coronary artery. In 2 patients in whom the problem was recognized retrospectively, an infarct developed; 1 patient died. In the 2 patients in whom the problem was apparent prior to infarction, nitroglycerin (1 to 3 micrograms/kg/min, intravenously) and nifedipine (10 mg, sublingually every 4 to 6 hours) successfully reversed the ischemic process. The routine administration of calcium at the completion of coronary revascularization may be ill-advised in patients in whom calcium channel blockers have been utilized. Postoperative therapy of this condition with intravenous administration of nitroglycerin and sublingual administration of nifedipine seems to be effective when instituted early.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6732337     DOI: 10.1016/s0003-4975(10)61133-2

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

1.  Coronary artery spasm occurring in the setting of the oculocardiac reflex.

Authors:  Henry R Kroll; Vivek Arora; David Vangura
Journal:  J Anesth       Date:  2010-06-05       Impact factor: 2.078

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

3.  Worsening of coronary spasm during the perioperative period: A case report.

Authors:  Hiroki Teragawa; Kenji Nishioka; Yuichi Fujii; Naomi Idei; Takaki Hata; Shuji Kurushima; Tomoki Shokawa; Yasuki Kihara
Journal:  World J Cardiol       Date:  2014-07-26

Review 4.  Stopping and restarting medications in the perioperative period.

Authors:  R Cygan; H Waitzkin
Journal:  J Gen Intern Med       Date:  1987 Jul-Aug       Impact factor: 5.128

Review 5.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 6.  Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Authors:  M Chaffman; R N Brogden
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

7.  Effect of flunitrazepam as an oral hypnotic on 24-hour blood pressure in healthy volunteers.

Authors:  Daniele Bosone; Roberto Fogari; Annalisa Zoppi; Angela D'Angelo; Natascia Ghiotto; Giulia Perini; Matteo Cotta Ramusino; Alfredo Costa
Journal:  Eur J Clin Pharmacol       Date:  2018-04-30       Impact factor: 2.953

8.  Reversible Cerebral Vasoconstriction Syndrome after Nifedipine Withdrawal.

Authors:  Mohammed H Alanazy; Ali Alwadei; Zaid F Alsaaran; Fahad A Essbaiheen
Journal:  Case Rep Neurol       Date:  2020-11-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.